Business Wire

Visa Welcomes the Nigerian Women’s Bobsled Team to Team Visa for the Olympic Winter Games PyeongChang 2018

Del

Visa (NYSE:V) today announced the addition of three athletes who make up the Nigerian Women’s Bobsled Team to Team Visa, currently training to become the first ever African representatives, men or women, to qualify for the Olympic Winter Games in the sport of Bobsled. Together, Bobsled pilot Seun Adigun, and brakemen Ngozi Onwumere and Akuoma Omeoga, combine their elite track backgrounds to chase their bobsled dreams.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171115005320/en/

Visa Welcomes the Nigerian Women’s Bobsled Team to Team Visa for the Olympic Winter Games PyeongChan ...

Visa Welcomes the Nigerian Women’s Bobsled Team to Team Visa for the Olympic Winter Games PyeongChang 2018. From left to right: brakeman Ngozi Onwumere, pilot Seun Adigun, and brakeman Akuoma Omeoga. (Photo: Business Wire)

Without access to proper training equipment or valuable ice time to perfect their skills, the members of the Nigerian Women’s Bobsled Team started their journey on the snow-less grounds of Houston, Texas, in a wooden sled they nicknamed ‘The Maeflower.’ Once the team set their sights on the Olympic Winter Games PyeongChang 2018, they established a crowdfunding website hoping to raise the much-needed funds to get to PyeongChang. Upon discovering the page, Visa was inspired by their story and determination to carve out a place in history and pledged to help solidify the team’s trip to the Olympic Winter Games.

“When we first heard their story we recognized the collective spirit of these athletes as a perfect fit for Team Visa,” said Chris Curtin, chief brand and innovation marketing officer at Visa. “By joining Team Visa, we hope to provide this group of determined athletes with a global stage to tell their story and inspire athletes all over the world to follow their dreams and never give up.”

The athleticism and determination of each member of the Nigerian Women’s Bobsled Team is palpable, as they push to rewrite history in their sport:

  • Seun Adigun (Nigeria, Bobsled Driver): Adigun represented Nigeria in the 100m hurdles at the London 2012 Olympic Games. Wanting to get back on the Olympic stage, she began training for bobsled in 2014.
  • Ngozi Onwumere (Nigeria, Bobsled Breakmen): Onwumere, a former competitive sprinter, clinched a Silver and Gold medal at the 2015 African Games in Republic of the Congo in the 200m and 4x100m relay, respectively. Onwumere started training after being recruited by Adigun in 2016.
  • Akuoma Omeoga (Nigeria, Bobsled Breakmen): Omeoga is a graduate of the University of Minnesota where she was a sprinter for the university’s track and field team, competing in the 100m and 200m races. The Olympic Winter Games PyeongChang 2018 will be the first time she is representing Nigeria.

“Already the support and encouragement we have felt as part of Team Visa has been a dream come true,” said Seun Adigun, driver of the Nigerian Women’s Bobsled Team. “We are proud to be part of a team that shares our mission and has connected us with the resources we needed to reach our goal, and hopefully empower others to do the same.”

Since the program began in 2000, Team Visa has supported over 400 Olympic and Paralympic Athletes and hopefuls by providing them with the tools, resources and support they need to reach their highest potential, regardless of origin or background. Team Visa features a diverse group of Olympic and Paralympic athletes who embody our core values – acceptance, partnership and innovation – and was cultivated with the global reach of the Olympic and Paralympic Games in mind.

The women of the Nigerian Women’s Bobsled Team joins Team Visa’s diverse roster of athletes, which includes: Mikaela Shiffrin (USA), Chloe Kim (USA), Gus Kenworthy (USA), Hilary Knight (USA), Oksana Masters (USA), Mark McMorris (Canada), Lee Sang-Hwa (South Korea), Kamil Stoch (Poland) and others.

For additional information on Team Visa, follow along at @VisaNews on Twitter and visit www.visa.com.

About Visa Inc.

Visa Inc. (NYSE:V) is the world’s leader in digital payments. Our mission is to connect the world through the most innovative, reliable and secure payment network - enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world, and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of connected commerce on any device, and a driving force behind the dream of a cashless future for everyone, everywhere. As the world moves from analog to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information, visit usa.visa.com/aboutvisavisacorporate.tumblr.com and @VisaNews.

Contact information

Visa Inc.
Bitsy Rich, 415-813-7252
erich@visa.com
or
Sarah Hamblen, 415-728-7268
shamblen@visa.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45Pressemelding

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10Pressemelding

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an